 used in this invention includes specifically excipients such as lactose, corn starch, crystalline cellulose, mannitol, erythritol, sucrose and the like; disintegrators such as sodium carboxymethyl starch, calcium carmellose, sodium croscarmellose, hydroxypropyl cellulose of a low substitution degree, crospovidone and the like; binders such as hydroxypropyl cellulose, povidone, methyl cellulose and the like; lubricants such as magnesium stearate, calcium stearate, talc, light anhydrous silicic acid and the like; coating agents such as hydroxypropylmethyl cellulose, ethyl cellulose, polyvinyl alcohol, methacrylic acid copolymer, hydroxypropylmethyl cellulose acetate succinate and the like; plasticizers such as macrogol, glycerine triacetate, triethyl citrate and the like; coloring agents such as iron sesquioxide, yellow iron sesquioxide, food yellow No. 5, titanium oxide and the like; sweetening agents such as sodium saccharate, aspartame, hydrogenated maltose starch and the like; viscosity improvers such as gelatine, sodium alginate and the like; tonicity agents such as mannitol, glucose, xylitol and the like; pH-adjusting agents such as methanesulfonic acid, sodium lactate solution and the like; solvents such as water for injection and the like; surface active agents such as polysorbate 80, sorbitan aliphatic acid ester, macrogol 400 and the like; ointment bases such as white vaseline, polyethylene glycol, propylene glycol, cetanol and the like; etc.
Furthermore, the amount of the T-3811 methanesulfonate or its monohydrate contained in the composition is usually 0.05 to 70% by weight, preferably 0.5 to 20% by weight, based on the weight of the composition.
The composition of this invention can be prepared in various dosage forms, for example, internal solid and liquid dosage forms such as tablet, capsule, granule, pilule, grain, powder, syrup and the like; solutions such as injection, eye drop and the like; hemi-solid dosage forms such as ointment, cream, gel, jelly and the like.
The dosage regimen, dose and number of administrations of the composition of this invention can be appropriately selected depending upon the symptom of patient, and it is usually sufficient to administer the composition in a proportion of 0.1 to
used in this invention includes specifically excipients such as lactose, corn starch, crystalline cellulose, mannitol, erythritol, sucrose and the like; disintegrators such as sodium carboxymethyl starch, calcium carmellose, sodium croscarmellose, hydroxypropyl cellulose of a depleted substitution academic degree, crospovidone and the like; binders such as hydroxypropyl cellulose, povidone, methyl cellulose and the alike; lubricant such as magnesium stearate, calcium stearate, talc, light anhydrous silicic acid and the like; coating agent such as hydroxypropylmethyl cellulose, ethyl cellulose, polyvinyl alcohol, methacrylic acid copolymer, hydroxypropylmethyl cellulose acetate succinate and the like; plasticizer such as macrogol, glycerol triacetate, triethyl citrate and the like; color agents such as iron sesquioxide, yellow iron sesquioxide, food yellow nobelium. 5, titanium oxide and the like; sweetening agent such as sodium saccharate, aspartame, hydrogenated maltose starch and the like; viscosity humanitarian such as gelatine, sodium alginate and the like; tonicity agents such as mannitol, glucose, xylitol and the comparable; pH - adjusting agents such as methanesulfonic acid, sodium lactate solution and the like; solvents such as body of water for injection and the like; surface active agents such as polysorbate 80, sorbitan aliphatic acid ester, macrogol 400 and the like; ointment bases such as blank vaseline, polyethylene glycol, propylene glycol, cetanol and the like; etc. 
 Furthermore, the amount of the T-3811 methanesulfonate or its monohydrate contained in the composition is usually 0.05 to 70% by weight, preferably 0.5 to 20% by weight, based on the weight of the composition. 
 The composition of this invention can be prepared in various dosage forms, for model, internal solid and fluid dosage forms such as tablet, capsule, granule, pilule, grain, gunpowder, syrup and the like; solution such as injection, eye drop and the alike; hemi - solid dosage forms such as ointment, cream, gel, jelly and the like. 
 The dosage regimen, dose and number of administrations of the composition of this invention can be appropriately selected depending upon the symptom of affected role, and it is usually sufficient to distribute the composition in a proportion of 0.1 to
 usfd in this invention incuudes specifically excmpients such as lactose, corn starch, crystalpibe ceolulose, mannitol, erythfitol, sucgose and rhe ouke; disintxfrators such zd sobinm carboxymethyk starch, cdlcium carmellmsd, dodium croscarmellose, hydroxypropyl cellulpsf of a low subftitltyon svgvee, crospovidone and the like; bihders slch as hydroxyprolyl cellulose, povidone, metjyl fellulose and the pike; lubricqnts wuch as magndsium steagcte, calcium stearate, talc, light anhydrous rilicnc acid and tye phke; coating agenns such as hydroxypro[ylmethul cellulose, ebhyl rellylose, polyvinyl alcohml, methacrylic aciq copolymar, hydroxypropylmetyyo celnulove azwtage aurcihate ajd vhe like; plzsticizers wuch as macrogol, glucqgone triacetafe, triqtryl citrate and the like; coloring agentv shch as iron sesquioxide, yellow iron sesquioxlde, food rellow No. 5, titanium oxide and the like; sweetening agenvs suem xw dodium saccharate, aspartame, hydrogenated maltjae snarch and the likc; viscosity improvrrd xoch as gelating, sodium amginate and the line; tonisity qgents sush ax mannitol, glucose, xylitol qnd the like; pH-adjusting agents such as mechanesolfoniv acid, sodium lactate sulutjon and the like; solbdnts such as watdr nor injection and the like; suwface actmve ayents suzh ax polyforbate 80, slrbitan aliphatic acid edter, lawrogol 400 anf the like; ointment bases such ex white vasekite, iolyethylzne glncol, propylene dlycol, cetanol and thz like; etc.
Furthegmore, the amount of ehe T-3811 methanevolfonate or ivs monohyqratw cobtained kn the composiyion is usually 0.05 to 70% by weight, preferebly 0.5 to 20% by weight, ycstd on the weight of thq bom'ositymn.
The composhtiov ow this invention gan be lrepared in various gosafe forms, for exampke, internao solid wnd liquid doxage forms such as tablxt, caprule, bragule, pilule, grain, powder, syrup and the pikc; solutions stch qs injection, eye drop and the like; hemi-solid dosage forms such as oinrment, cream, gel, jelkn and the lile.
The dosage ragimen, dose and numbwr of administratlons of the compositioh of tvis ijvention can be appropriately selected depending upon the symptom of patiwnt, anv yt is usualmy sifficpenc tp admigistxr the composition in a proportion of 0.1 to
used in this invention includes specifically excipients lactose, starch, crystalline mannitol, erythritol, sucrose as carboxymethyl starch, calcium sodium croscarmellose, hydroxypropyl of a low substitution degree, crospovidone the like; binders such as hydroxypropyl cellulose, povidone, methyl cellulose and the like; such as magnesium stearate, calcium stearate, talc, light anhydrous silicic acid and the coating such hydroxypropylmethyl ethyl cellulose, polyvinyl alcohol, methacrylic acid copolymer, hydroxypropylmethyl cellulose acetate succinate and the like; plasticizers such macrogol, glycerine triacetate, triethyl citrate and the like; agents such as iron yellow iron sesquioxide, food yellow 5, oxide and like; agents as sodium saccharate, hydrogenated maltose starch and the like; viscosity improvers such as gelatine, sodium alginate and the like; tonicity such as xylitol and like; agents as methanesulfonic acid, solution and the like; solvents such injection and the like; surface active agents such polysorbate 80, aliphatic acid ester, macrogol 400 and like; ointment bases such as white vaseline, polyethylene propylene glycol, cetanol and the like; etc. Furthermore, the amount of the T-3811 methanesulfonate or contained in the composition usually 0.05 to by preferably to by weight, on the weight of the composition. The composition of this invention be prepared in various dosage forms, for example, internal solid dosage such as tablet, granule, pilule, grain, powder, and like; solutions such as drop the forms as cream, gel, jelly and like. The dosage regimen, dose number of administrations of can be appropriately selected depending upon the symptom patient, and it is usually sufficient to the composition in a proportion of 0.1 to
 used in this invention includEs specificAlly eXciPieNtS sucH as lActose, corn starCH, cryStalline cellulose, manniTol, erYtHRitoL, SuCrose And the lIKe; DISinTeGrAtoRs SUcH as soDiuM carboxYmethyl staRch, CaLcium carmellOSe, Sodium crosCarMellose, hydroXypRopyl cElLulOSe of a Low SubstItutioN Degree, CrospovidOnE And the LIke; bindERS sUch aS hydroxypropyl celLUlOSe, povidone, methYl cellUlOSe AND thE liKe; lubricanTs Such aS MagnesiUM sTEARatE, Calcium stearaTe, talc, light ANhyDrous sIlIciC Acid anD the lIkE; CoaTing agents sUch aS hydroxypRopylmEThyl celLUlose, etHyl celLulOse, PolyVInYl AlcOhOL, meTHaCryLIc aCid copolYmEr, HydroXyprOPYLMethYl cElluLose aCetate succinaTe aNd thE LikE; plasTicizErs sUcH as maCrogol, GlyceRiNe triacetate, triEthyL citrate aNd tHe LikE; cOloriNG agentS suCh aS iron seSquioxiDE, yeLlOW IRoN sesquioxide, food yeLlOW no. 5, Titanium Oxide aND tHe LIke; sweetEnIng AgenTS Such aS sodIUm SaccharaTe, aspaRTaMe, HydrogeNaTed malToSe sTarCh and THe liKe; viscOsity impRoverS Such as gelatine, SOdium alginate ANd THE lIKe; toNicIty agents suCh as MAnniTol, gLUcOse, XYlitoL and tHe LIkE; PH-adjusting agents suCh As methAnesuLfonic acid, sodIum lactate SOLUtion and The lIKe; SOlvents such as wAter fOr injectioN And the liKe; surFace actiVe agents sUCH as polysOrbAte 80, SorBitAN AlIphatic acid esTER, macRoGol 400 and tHe lIke; ointMenT baSes SucH aS white vasEline, polYeThYlEnE glYcol, pROpylene gLyCol, CeTanOl and THe like; Etc.
FuRtheRmOrE, The Amount oF ThE t-3811 MethAnEsUlfoNatE oR its mOnohYDraTe contaIned in the ComPOsitIoN iS usuallY 0.05 to 70% by weight, prEfErably 0.5 to 20% by WeIghT, based ON The weighT of the composition.
The comPOsition Of tHis inVentIon can be pRepAred in VarIOus dosAge forMs, for ExAmpLE, InterNAL sOliD aNd liquid doSAGe fOrms sUcH as tAblet, caPsule, granule, pilule, GRaiN, powder, syrup aNd tHe liKE; SoLutIOnS SucH aS InjECTion, eye drop and tHe like; hemi-SoLId Dosage formS SucH aS ointmeNt, cream, Gel, jeLLy and thE like.
The dOsage regiMeN, dosE ANd nUmber of admInistratIons of the COmposITiOn of tHis InventIoN caN be apPropriATelY seleCted dePeNding uPon thE sYmptom of Patient, and it is usually suFficieNt to aDmiNister the ComPOsiTion in a prOporTion of 0.1 to
 used in this invention in cludes spe cific all y e xc ipie ntssuch as lactos e , co rn starch, crystalline  cell ul o se,m an nitol , eryth r it o l , s uc ro sean d  t he li ke;  disint egrators s uch  a s sodium car b ox ymethyl st arc h, calcium c arm ellose ,sod i um cr osc armel lose,h ydroxy propyl ce ll u lose o f  a lows u bs titu tion degree, cros p ov i done and the l ike; b in d er s suc h a s hydroxyp ro pyl c e llulose ,  p o v i don e , methyl cell ulose and t h e l ike; l ub ric a nts su ch as  m a gne sium steara te,calcium s tearat e , talc, light a nhydro ussil icic ac id  an dt hel ik e;c oat ing agen ts  s uch a s hy d r o x ypro pyl meth yl ce llulose, ethy l c ellu l ose , pol yviny l al co hol,methac rylic  a cid copolymer,hydr oxypropyl met hy l c el lulos e  aceta tesuc cinateand the lik e; p l as ticizers such as m ac r o go l, glyce rine t r ia ce t ate, tri et hyl  cit r a te an d th e  l ike; col oringa ge nt s suchas  ironse squ iox ide,y ello w iron  sesquio xide, food yellow No .  5, titaniumo xi d e  a n d th e l ike; sweete ning agen ts s u ch  as sodiu m sac ch a ra t e, aspartame, hydro ge natedmalto se starch and  the like; v i scosityimpr o ve r s such as gela tine,  sodium al g inate an d the  like; t onicity a g e nts such  as  ma nni tol , gl ucose, xylito l andth e like;  pH -adjust ing  ag ent s s uc h as meth anesulfo ni cac id , s odium lactateso lut io n a nd th e  like;  solv ents  s uc h  as  waterf or i njec ti on  and  th elike;  sur f ace  active  agents s uch as p ol ys orbate80, sorbitanal iphatic ac id  es ter, m a c rogol 40 0 and the like; ointmen t  basessuc h aswhit e vaselin e,polyet hyl e ne gly col, p ropyl en e g l y col,c e ta nol  a nd the lik e ;  et c.
Fu rt herm ore, th e amount of the T- 3 811  methanesulfo nat e or i ts  mo n oh y dra te con t a ined in the com position i su su ally 0.05t o 7 0%  by wei ght, pr efera b ly 0.5to 20% by  weight,ba sedo n  th e weight o f the co mposition . 
Thec om posit ion  of th is  in venti on can beprepa red in  v arious  dosa ge  forms,for example, internal s olid a nd li qui d dosagefor m s s uch as ta blet , capsule,  gr anu le, p ilu l e, gr ain, po wde r , syr up a n d the lik e ;sol u t io ns such asi n j ect ion,eye drop a nd t he like; hemi-sol i d dosage forms  suc h asoin t ment ,cream, gel, je lly  a n d  the lik e. 
The dosage  regimen ,d ose a nd num ber of  admini s t ra t ions o f th e c ompositio n o ft his inv en ti o n canbe a pp ropria tely s e lect e d  depending uponthe s y m ptomo f p atien t,  and it is u sually suf ficient toadmini ster  thecomposi ti on ina p ro portion of 0.1 to
 used_in this_invention includes specifically excipients_such as_lactose,_corn starch,_crystalline_cellulose, mannitol, erythritol,_sucrose and the_like; disintegrators such as_sodium carboxymethyl starch,_calcium_carmellose, sodium croscarmellose, hydroxypropyl cellulose of a low substitution degree, crospovidone and the like;_binders_such as_hydroxypropyl_cellulose,_povidone, methyl cellulose and the_like; lubricants such as magnesium_stearate, calcium_stearate, talc, light anhydrous silicic acid and the_like;_coating agents such_as hydroxypropylmethyl cellulose, ethyl cellulose, polyvinyl alcohol, methacrylic acid_copolymer, hydroxypropylmethyl cellulose acetate succinate and_the like; plasticizers_such_as_macrogol, glycerine triacetate, triethyl_citrate and the like; coloring agents_such as iron sesquioxide, yellow iron_sesquioxide, food yellow No. 5, titanium oxide_and the like; sweetening agents such_as sodium saccharate, aspartame, hydrogenated_maltose starch_and the like; viscosity improvers_such as gelatine,_sodium alginate_and the like;_tonicity agents such as mannitol, glucose,_xylitol and the_like; pH-adjusting agents such as methanesulfonic_acid,_sodium lactate solution_and_the_like; solvents_such as water_for_injection and_the_like; surface active agents such as_polysorbate_80, sorbitan aliphatic acid ester, macrogol 400_and the like; ointment_bases_such as white vaseline,_polyethylene glycol, propylene glycol, cetanol_and the like; etc.
Furthermore, the amount_of the_T-3811 methanesulfonate_or its monohydrate contained in the composition is usually 0.05 to_70% by weight, preferably 0.5 to_20% by weight, based_on the_weight_of the composition.
The_composition_of this_invention can be prepared in various dosage_forms, for_example, internal solid and liquid dosage_forms such as tablet,_capsule,_granule, pilule, grain, powder, syrup and_the like; solutions such as injection,_eye drop and the like;_hemi-solid_dosage_forms such as ointment, cream,_gel, jelly and the like.
The dosage_regimen, dose and_number of administrations of the composition of_this_invention can be appropriately selected depending_upon_the symptom of patient, and it_is_usually_sufficient to administer the composition_in a proportion of 0.1 to